Environmental Engineering Reference
In-Depth Information
11 Research and Development
of a New Safe Form of Drugs
T.G. Tolstikova, A.A. Onischuk, I.V. Sorokina,
A.M. Baklanov, V.V. Karasev, V.V. Boldyrev, V.M. Fomin,
M.V. Khvostov, A.O. Bryzgalov, and G.A. Tolstikov
CONTENTS
11.1 Part I. Physical-Chemical and Toxic-Pharmacological Characteristics
of Aerosols Form of Drugs ................................................................................................... 250
11.1.1 Introduction .............................................................................................................. 250
11.1.2 Synthesis of Nanoaerosol.......................................................................................... 251
11.1.2.1 Aerosol Size, Concentration, and Composition ...................................... 254
11.1.2.2 Lung-Deposited Dose.............................................................................. 255
11.1.2.3 Analgesic Effect of Ibuprofen Nanoaerosol............................................ 258
11.1.2.4 Anti-Inlammatory Effect of Indomethacin Nanoaerosol....................... 258
11.1.2.5 Morphology of the Lungs........................................................................ 259
11.1.3 Conclusions............................................................................................................... 261
References...................................................................................................................................... 263
11.2 Part II. Study of the Toxic-Pharmacological Properties of Nanostructured drug forms ..... 264
11.2.1 Introduction ..............................................................................................................264
11.2.1.1 Glycyrrhizic Acid.................................................................................... 265
11.2.1.2 Complexes of Pharmacons with Glycyrrhizic Acid................................ 266
11.2.1.3 Complexes of Nonsteroid Anti-Inlammatory Drugs with
Glycyrrhizic Acid.................................................................................... 267
11.2.1.4 Complexes of Prostaglandins with Glycyrrhizic Acid as a New
Group of Uterine Tonics.......................................................................... 268
11.2.1.5 Complexes of Glycyrrhizic Acid with Cardiovascular Drugs ................ 269
11.2.1.6 Complex of Glycyrrhizic Acid with Indirect Oral Anticoagulant
Warfarin .................................................................................................. 271
11.2.1.7 Complexes of Glycyrrhizic Acid with Psychotropic Drugs .................... 272
11.2.1.8 Complexes of Glycyrrhizic Acid with Antitumor Drugs ........................ 274
11.2.1.9 Complexes of Glycyrrhizic Acid with Antimicrobial Drugs .................. 274
11.2.1.10 Complexation with Hypocholesterolemic Agent Symvastatin................ 274
11.2.1.11 Antidote and Antiradical Activity of Complexes of Glycyrrhizic
Acid with Uracil Derivatives................................................................... 275
11.2.1.12 Stevia rebaudiana (Bertoni) ................................................................... 276
11.2.1.13 Complexes with Stevioside and Rebaudioside ........................................ 276
11.2.1.14 Arabinogalactan ...................................................................................... 278
11.2.1.15 Complexes with Arabinogalactan ........................................................... 279
References...................................................................................................................................... 281
249
 
Search WWH ::




Custom Search